Allergy Treatment Market Comprehensive Study by Leading Key Players: GlaxoSmithKline, ALK-Abelló A/S, Sallergenes Greer, Allergy Therapeutics, Sanofi SA, Johnson & Johnson, Merck Co. In, Merck KGaA, F. Hoffmann-La Roche AG, and Allergan plc.

The Allergy Treatment Market is estimated at $ 24.653 billion in 2017 and is expected to reach $ 40.36 billion by 2025, growing at a CAGR of 6.3% from 2018 to 2025. Depending on the type of rhinitis and asthma sector accounted for more than half of the total market share in 2017.

Allergies are defined as hypersensitivity reactions to various foreign substances by the immune system. Allergic substances are called allergens. Examples include pollen, dust mites, mold, pet dandruff, certain foods, and others. Patients with allergies are called allergies or atopy. The market for allergy therapies is expected to grow at a rapid pace as new therapies for allergic specific drugs are developed, immunotherapy emerges, and allergies are increasing worldwide.

Depending on the type of rhinitis, Rhinitis has made the highest return in 2017 and is expected to maintain this superiority throughout the forecast period. This is due to the increased prevalence of allergic rhinitis worldwide. For example, according to the European Society of Allergy and Clinical Immunology (EAACI), about 400 million people suffer from rhinitis. However, the food allergy segment is expected to register the highest growth rate during the forecast period.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/3541?utm_source=sy-Openpr

The report provides an extensive competitive analysis and profiles of the key market players, such as
• GlaxoSmithKline
• ALK-Abell A/S
• Sallergenes Greer
• Allergy Therapeutics
• Sanofi SA
• Johnson & Johnson
• Merck Co. In
• Merck KGaA
• F. Hoffmann-La Roche AG
• Allergan plc.

The other players in the value chain (not included in the report) include Sunovion Pharmaceuticals Inc., Teva Pharmaceuticals, HAL Allergy Group, Collegium Pharmaceutical, Inc., Procter & Gamble, Circassia, and Novartis AG.

Get Discount UP To 25% * Offer Till 31st Dec 2018@ https://www.alliedmarketresearch.com/checkout/66621?utm_source=sy-Openpr

Key Findings of the Allergy Treatment Market:
• Based on type, the rhinitis and asthma segments dominated the global allergy treatment market in 2017 and are expected to maintain this trend during the forecast period.
• Based on treatment, the immunotherapy segment is expected to register the highest CAGR of 8.5% from 2018 to 2025.
• U.S. generated the highest revenue in the global allergy treatment market in 2017, accounting for more than half of the market in North America.
• Asia-Pacific was the highest contributor in the allergy treatment market in 2017 and is anticipated to experience rapid growth during the forecast period.

North America was the leading revenue contributor to the global market in 2017, owing to increase in healthcare investments by manufacturers, surge in R&D expenditure for the development of allergy treatment, and growth in prevalence of food allergies. Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to increase in prevalence of allergic asthma owing to rise in pollution, surge in internet penetration, and rise in awareness about allergies.

Access Full Summery @ https://www.alliedmarketresearch.com/allergy-treatment-market?utm_source=sy-Openpr

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.